Company news
Korro Bio, Inc. news in 2022
Korro Bio, Inc.'s news releases, calls and decks from 2022, newest first.
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
December 18, 2022
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
December 14, 2022
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
November 16, 2022
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
November 7, 2022
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
October 11, 2022
Frequency Therapeutics to Participate in September Investor and Medical Conferences
August 29, 2022
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
August 8, 2022
Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
May 17, 2022
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
May 3, 2022
Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
April 21, 2022
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
March 14, 2022
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
February 27, 2022
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022